Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

r, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral T
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Lehigh Valley Health Network ... TM devices, adding to its existing arsenal of ... taking up residence within the network, LVHN is now ... to proactively combat superbugs and provide the best possible ... Room Ultraviolet Disinfector, TRU-D – the signature product of ...
(Date:5/21/2013)... SUNNYVALE, Calif. , May 21, 2013 /PRNewswire/ ... ), announced today the publication of study results ... the CyberKnife® Robotic Radiosurgery System, the most widely ... (SBRT). The study followed 304 patients for a ... years post-treatment and found that 97 percent of ...
(Date:5/21/2013)... 21, 2013  Janssen R&D Ireland (Janssen) today ... global Phase 3 PROMISE study demonstrating that use ... to sustained virologic response 12 weeks after the ... treatment-experienced genotype 1 chronic hepatitis C adult patients ... liver fibrosis, when administered once daily with pegylated ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
(Date:5/21/2013)... 21, 2013 Five million Americans will ... who do, Tiffany Liashek, owner of Studio South ... a long look at credentials and experience. The variation ... she says. “A trainer can pay $69.50 and get ... , Good trainers invest in themselves, A serious, professional ...
(Date:5/21/2013)... 2013 Third Generation Master Barber Greg ... first two barbering DVDs. These DVDs include content from ... school , cosmetology school or are current professionals, will ... an experienced teacher and mentor. , Today’s modern men’s ... 1920’s – 1960’s time period. In order to efficiently ...
(Date:5/21/2013)... May 21, 2013 Dallas-based TopMD™ Skin ... journal article testing the efficacy of their flagship product, ... The clinical study results appear in the May/June 2013 ... article, “A Novel Sodium Hypochlorite Cleanser Shows Clinical Response ... reports impressive findings seen after consistent use of the ...
(Date:5/21/2013)... Everspark Interactive, one of the city's leading online marketing ... past year – and announced another milestone this week ... for Kids II, a designer of innovative baby toys ... effort, specializing in search engine optimization (SEO) or the ... The company now offers a host of boutique online ...
(Date:5/21/2013)... Beginning May 21st, 2013, DTP Sales ... 8000, the newest in digital recording technology, to the ... product for anyone looking to get the most from ... 8000 is expected to have revolutionary options and ... voice recorder features and highlights: , ...
Breaking Medicine News(10 mins):Health News:Sarasota Fitness Tips: Choosing a Safe Trainer and Gym 2Health News:Sarasota Fitness Tips: Choosing a Safe Trainer and Gym 3Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 2Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 3Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 4Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 5Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 6Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 2Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 3Health News:Everspark Named Interactive Marketing Company for Kids II 2Health News:DTP Sales & Service Announces Upcoming Availability Of Philips Pocket Memo 8000 Series 2
... They could fight cancer, heart disease, researchers say , , MONDAY, ... your life, a new European study suggests. , "The ... mortality from any cause of death," said lead researcher Dr. ... in Lyon, France. , The new finding, published in the ...
... the Association for Assessment and Accreditation of Laboratory ... standard for animal care facilities, AAALAC accreditation is ... the humane care and use of animals in ... involves a comprehensive review by AAALAC evaluators, who ...
... out-of-pocket health care costs, CAMP HILL, Pa., Sept. ... to help consumers compare health plan options and,choose one ... is available,to consumers on Highmark member Web sites. ... said Kim,Bellard, Vice President of eMarketing and Customer Relationship ...
... 10 portionpals(R), the fastest growing,weight loss tool ... million,sales mark with no national retail distribution in ... are coming strictly from word-of-mouth," says Matt,Zucker, VP ... Moose,of Manistique, Michigan became our 250,000 customer! "Our ...
... researchers have found that first-degree relatives (i.e., parents, siblings, ... more likely to have the biomarker of the disease ... could screen and assess first-degree relatives of PBC patients ... and treat more patients before the disease causes irreversible ...
... well after therapy ends , , MONDAY, Sept. 10 (HealthDay ... breast cancer survivors still report more days of fatigue ... fatigue is likely a long-term effect of chemotherapy, according ... complaint for most people and is also reported by ...
Cached Medicine News:Health News:Vitamin D Supplements May Lengthen Life 2Health News:UCSF animal care facility receives top accreditation 2Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2Health News:New research may lead to earlier diagnosis and treatment of primary biliary cirrhosis in families 2Health News:Long-Term Fatigue Plagues Cancer Survivors 2
... Sun Design chairs offer support and ... of the chair are designed to take ... maximum comfort. The seat height and angle ... a single lever. The seat can be ...
Heine Beta 200 Streak Retinoscope 2.5v...
Video Equipment...
Portable mini halogen light....
Medicine Products: